ADAlexandre Denadai-Souza

Alexandre Denadai-Souza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexandre Denadai-Souza has a total of 425 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Human Gut Cell Atlas v1.0: A Unified, Community-Built Reference of Cellular Diversity Across the Gut

    by Kyle Kimler, Christopher Lance, Balazs Bohar, Abdalla Ahmed, Ran Zhou, Raquel Bartolome-Casado, Victoria Gudino, Ricardo O. Ramirez Flores, Fredrik V. Junghus, Urs M. Morbe, et al.

    Single-cell RNA-sequencing (scRNA-seq) studies have transformed our understanding of cellular diversity in the human intestine, but differences in anatomical sampling, experimental processing and cell-type nomenclature limit comparison across datasets. Here, we present the Human Gut Cell Atlas (HGCA) V1, a community-curated reference of 944,390 healthy and disease-adjacent intestinal cells from 502 samples, 265 donors and 24 landmark studies, linked to detailed anatomical, clinical, and technical metadata. As this metadata is of critical importance to human biology, we developed MetaManager, an open source data management framework for standardized metadata collection and tracking. A five-level consensus taxonomy resolves 94 homeostatic cell identities and enables transferrable, high-resolution annotation of new gut datasets. By assembling cell identity, sampling metadata, and independent spatial validation, intestinal segment and radial tissue depth were revealed to systematically shape cellular composition and transcriptional state, enabling inference of the presence of sampling-dependent tissue niches, including lymphoid follicles. Reference mapping accurately and rapidly recovered cohort-level Crohn’s disease and treatment signatures without de novo annotation, while mapping human intestinal organoids quantified cell-type-specific identity, regional specification, maturation, and transcriptional fidelity to native tissue. The HGCA V1 provides a standardized cellular, anatomical coordinate, and metadata system for reproducible, high-quality analysis of intestinal biology across healthy tissue, disease-associated remodelling, and experimental models, providing a continuously evolving community reference for cumulative discovery in human intestinal biology.

  • Open Access

    Amphiregulin promotes remyelination by reprogramming microglia and priming OPC differentiation

    by Lidia Yshii, Sadia Shaukat, Justine Fiefvet, Melanie Loix, Elodie Modave, Melissa Schepers, Matthias van Sligtenhorst, Nina Dedoncker, Gabriel Henrique Caxali, Guy Boeckxstaens, et al.

    Remyelination failure is a central obstacle in demyelinating diseases, yet the endogenous signals coordinating CNS repair remain poorly defined. Here we identify amphiregulin (AREG), an EGFR ligand produced by regulatory immune cells during peripheral tissue repair, as a coordinator of central nervous system remyelination. Systemic AAV delivery drives astrocytic AREG expression in the mouse brain and enhances myelin recovery following cuprizone-induced demyelination, with increased OPC density and reduced CD68hi microglia. Single-cell RNA sequencing shows that AREG reprograms CD68+ microglia toward a homeostatic, debris-clearing state and primes OPCs for differentiation through downregulation of developmental transcripts and upregulation of pro-differentiation genes. Cell–cell communication analysis nominates the microglia-to-oligodendrocyte Psap–GPR37 axis as a candidate effector, with GPR37 protein rescued by AREG. Recombinant AREG enhances the differentiation of human iPSC-derived OPCs. These findings establish astrocyte-delivered AREG as an endogenous coordinator of glial crosstalk during remyelination and identify EGFR-ligand signaling as an entry point for pro-remyelinating therapies.

  • Single-nucleus profiling reveals hepatocyte identity and immune features associated with corticosteroid response in severe alcohol-related hepatitis

    by Lukas Van Melkebeke, Markus Boesch, Tessa Ostyn, Wenxin Huang, Cansu Akkaya, Matthias van Sligtenhorst, Dania El Abyad, Fateme Safaeifard, Alexander Dumarey, Marie Wallays, et al.


  • Open Access

    Cirrhosis-associated immune dysfunction reflects impaired intestinal CD8αβ⁺ intraepithelial lymphocyte compartmentalization

    by Cansu Akkaya, Matthias van Sligtenhorst, Sadia Shaukat, Elodie Modave, Alexander Dumarey, Gabriel Henrique Caxali, Astrid Verbiest, Lise de Meyere, Stiene Vrancken, Lize van Meerbeeck, et al.

    Summary: Bacterial infections are major drivers of decompensation and mortality in cirrhosis, yet the mechanisms underlying cirrhosis-associated immune dysfunction remain incompletely understood. Although current models frequently invoke adaptive immune exhaustion, intestinal intraepithelial lymphocytes (IELs), a central barrier immune compartment responsible for epithelial surveillance and microbial containment, have remained largely unexplored in cirrhosis. Here, we performed integrated immune profiling of paired duodenal biopsies and peripheral blood from healthy volunteers and patients with compensated or decompensated cirrhosis using spectral flow cytometry, plasma proteomics, immunofluorescence, and single-cell RNA sequencing. The healthy duodenal epithelium was dominated by CD8αβ⁺ IELs, whereas cirrhosis was associated with marked depletion of these cells together with expansion of innate cytotoxic populations. Residual IELs exhibited attenuation of antimicrobial transcriptional programs alongside enrichment of innate-like cytotoxic pathways. Loss of CD8αβ⁺ IELs was associated with coordinated reduction of CCR9 surface expression across circulating and mucosal CD8⁺ T-cell compartments together with persistent systemic elevation of CCL25. In contrast, circulating lymphocytes retained functional competence and lacked enrichment of canonical exhaustion markers despite progressive inflammatory remodeling. Collectively, these findings identify defective intestinal IEL compartmentalization as a central feature of cirrhosis-associated immune dysfunction and implicate dysregulation of the CCL25–CCR9 axis in impaired mucosal immune surveillance. Highlights: Cirrhosis-associated immune dysfunction reflects defective mucosal immune compartmentalization rather than global adaptive immune paralysis Circulating lymphocytes retain effector function and do not exhibit canonical exhaustion phenotypes CD8αβ⁺ intraepithelial lymphocytes are selectively depleted from the duodenal epithelium in cirrhosis Persistent systemic CCL25 elevation is associated with coordinated CCR9 loss across mucosal and circulating CD8⁺ T-cell compartments

  • Open Access

    Regional partitioning of colorectal epithelial cells is altered in gastrointestinal disorders without overt inflammation

    by Alexandre Denadai-Souza, Elodie Modave, Ceyhun Alar, Yan Wu, Javier Escudero Morlanes, Leire Alonso Galicia, Cansu Akkaya, Matthias van Sligtenhorst, Xesus Abalo, Ludvig Larsson, et al.

    The intestinal epithelium integrates host- and environment-derived cues to coordinate barrier defense, nutrient absorption, and fluid homeostasis 1-3. Single-cell atlases have delineated key regional differences between the small and large intestines and revealed extensive epithelial rewiring in inflammatory gastrointestinal diseases. However, whether comparable epithelial alterations occur in the absence of active inflammation remains unknown. In particular, the epithelial landscape in functional gastrointestinal disorders, such as irritable bowel syndrome (IBS), as well as in symptomatic patients with Crohn’s disease (CD) in remission, has not been defined. Here, using integrated single-cell and spatial transcriptomics, we generate a high-resolution map of the human colorectal epithelium across health, IBS, and symptomatic CD remission. In healthy tissue, we identify robust regional partitioning within absorptive lineages, with the rectum exhibiting transcriptional programs biased towards chloride secretion. Strikingly, in IBS and symptomatic CD remission, we observe the emergence of ectopic epithelial programs despite the absence of overt inflammation. These include antigen-sampling microfold cells in the rectum of patients with IBS and two aberrant absorptive subsets in the ascending colon of symptomatic CD patients in remission, both transcriptionally enriched for antigen sampling and chloride secretory pathways. Together, these findings reveal previously unrecognized epithelial rewiring that emerges or persists in patients with debilitating gastrointestinal symptoms despite the absence of overt inflammation.

  • Open Access

    Hydrogen sulfide rescues IFNγ/TNFα-induced intestinal epithelial barrier dysfunction by enhancing oxidative phosphorylation

    by Janaíne Prata de Oliveira, Matthias van Sligtenhorst, Cansu Akkaya, Astrid Verbiest, Victoria Francelino Alves, Marie Wallays, Schalk van der Merwe, Marc Ferrante, Tim Vanuytsel, John L. Wallace, et al.

    The intestinal epithelial barrier is essential for protection against pathogens and toxins while allowing nutrient and water absorption. Barrier dysfunction is increasingly recognized as a key pathophysiological mechanism in diseases affecting the gastrointestinal (GI) tract and distant organs. Hydrogen sulfide has emerged as an important regulator of intestinal homeostasis. This study investigates the effects of the H₂S-releasing compound 4-hydroxithiobenzamide (TBZ) on epithelial barrier integrity. Although TBZ did not prevent interferon-γ and tumor necrosis factor-α (IFN/TNF)-induced epithelial cell death, it reversed cytokine-induced increases in transepithelial permeability. Notably, TBZ alone increased paracellular permeability but normalized it under inflammatory conditions, indicating a context-dependent effect. H₂S-producing enzymes localized apically in IECs, suggesting subcellular regulation. Transcriptomic analysis identified oxidative phosphorylation as a pathway mediating TBZ’s effects. Functional studies confirmed that TBZ enhances oxidative phosphorylation, while inhibition of complex IV abolished barrier protection. In conclusion, our data indicate that hydrogen sulfide counteracts IFN/TNF-induced epithelial barrier dysfunction through transcriptional and functional enhancement of oxidative phosphorylation.


  • Intestinal blood vessel-associated macrophages and gut-vascular barrier dysfunction in cirrhosis

    by Lena Smets, Maria Francesca Viola, Markus Boesch, Jana Raman, Lukas Van Melkebeke, Max Nobis, Emilio Flint, Nika Pajk, Paola Brescia, Alessandra Silvestri, et al.

    Background: Bacterial translocation in cirrhosis can trigger infection and hepatic decompensation, leading to systemic inflammation, organ failure and increased mortality. These infections often originate from the gastrointestinal tract after bacteria breach the intestinal barrier and disseminate to systemic sites. Objective: In this study, we explore the mechanisms underlying intestinal barrier dysfunction in cirrhosis using an experimental cirrhosis model and patient-derived intestinal biopsies. Design: We developed a murine model of cirrhosis through chronic administration of carbon tetrachloride for up to 20 weeks. We investigated both the intestinal epithelial and vascular compartments and performed single-cell transcriptomic profiling of myeloid cells isolated from cirrhotic mice and from individuals with compensated and decompensated cirrhosis. Results: Our findings indicate that bacterial translocation in cirrhosis is the result of failure at multiple checkpoints, including aberrant epithelial cell death, vascular barrier damage and dysfunction of gut-vascular macrophages. In a preclinical model of cirrhosis, macrophages exhibited increased levels of monocyte-attracting chemokines, reduced bacterial clearance and impaired interactions with blood vessels. Importantly, depleting vascular-lining macrophages resulted in bacterial translocation to systemic sites, even in the absence of experimental liver disease. Transcriptional profiling of macrophages from duodenal biopsies of patients with cirrhosis indicated similar dysregulation of pathways supporting blood vessels and elevated expression of chemokines. Conclusions: This study emphasises the critical role of intestinal macrophages in preventing the dissemination of luminal bacteria and highlights the multifaceted breakdown of the intestinal barrier in cirrhosis and the importance of the gut-vascular barrier.


  • Open Access

    Fecal Proteolytic Bacteria and Staphylococcal Superantigens Are Associated With Abdominal Pain Severity in Irritable Bowel Syndrome

    by Runze Quan, Lisse Decraecker, Iris Appeltans, María Cuende-Estévez, Samuel Van Remoortel, Javier Aguilera-Lizarraga, Zheng Wang, Gareth Hicks, Jill Wykosky, Peter McLean, et al.

    INTRODUCTION: Changes in the composition of the gut microbiota have been associated with the development of irritable bowel syndrome (IBS). However, to what extent specific bacterial species relate to clinical symptoms remains poorly characterized. We investigated the clinical relevance of bacterial species linked with increased proteolytic activity, histamine production, and superantigen (SAg) production in patients with IBS. METHODS: Fecal (n = 309) and nasal (n = 214) samples were collected from patients with IBS and healthy volunteers (HV). Clinical symptoms and gut transit time were evaluated. Bacterial abundance in feces and nasal swabs as well as fecal trypsin-like activity were assessed. RESULTS: The percentage of fecal samples containing Staphylococcus aureus was significantly higher in IBS compared with HV. Forty-nine percent of S. aureus–positive fecal samples from patients with IBS were also positive for SAgs, compared with 12% of HV. Patients with IBS and positive fecal SAg-producing S. aureus reported higher pain scores than those without S. aureus. Moreover, increased fecal proteolytic activity was associated with abdominal pain. Fecal abundance of Paraprevotella clara and Alistipes putredinis was significantly decreased in IBS, particularly in samples with higher proteolytic activity. Patients with lower Alistipes putredinis or Faecalibacterium prausnitzii abundance reported more severe abdominal pain. DISCUSSION: In keeping with our preclinical findings, we show that increased presence of SAg-producing S. aureus in fecal samples of patients with IBS is associated with increased levels of abdominal pain. We also show that increased fecal proteolytic activity is associated with increased abdominal pain in patients with IBS.


  • Open Access

    Distinct immunometabolic signatures in circulating immune cells define disease outcome in acute-on-chronic liver failure

    by Rita Feio-Azevedo, Markus Boesch, Silvia Radenkovic, Lukas van Melkebeke, Lena Smets, Marie Wallays, Bram Boeckx, Gino Philips, Janaíne Prata de Oliveira, Mohammad Ghorbani, et al.

    Background and Aims: Acute-on-chronic liver failure (ACLF) is a complication of cirrhosis characterized by multiple organ failure and high short-term mortality. The pathophysiology of ACLF involves elevated systemic inflammation leading to organ failure, along with immune dysfunction that heightens susceptibility to bacterial infections. However, it is unclear how these aspects are associated with recovery and nonrecovery in ACLF. Approach and Results: Here, we mapped the single-cell transcriptome of circulating immune cells from patients with ACLF and acute decompensated (AD) cirrhosis and healthy individuals. We further interrogate how these findings, as well as immunometabolic and functional profiles, associate with ACLF-recovery (ACLF-R) or nonrecovery (ACLF-NR). Our analysis unveiled 2 distinct states of classical monocytes (cMons). Hereto, ACLF-R cMons were characterized by transcripts associated with immune and stress tolerance, including anti-inflammatory genes such as RETN and LGALS1. Additional metabolomic and functional validation experiments implicated an elevated oxidative phosphorylation metabolic program as well as an impaired ACLF-R cMon functionality. Interestingly, we observed a common stress-induced tolerant state, oxidative phosphorylation program, and blunted activation among lymphoid populations in patients with ACLF-R. Conversely, ACLF-NR cMon featured elevated expression of inflammatory and stress response genes such as VIM, LGALS2, and TREM1, along with blunted metabolic activity and increased functionality. Conclusions: This study identifies distinct immunometabolic cellular states that contribute to disease outcomes in patients with ACLF. Our findings provide valuable insights into the pathogenesis of ACLF, shedding light on factors driving either recovery or nonrecovery phenotypes, which may be harnessed as potential therapeutic targets in the future.


  • Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: a randomised, double-blind, placebo-controlled trial

    by Lisse Decraecker, Danny De Looze, David P Hirsch, Heiko De Schepper, Joris Arts, Philip Caenepeel, Albert J Bredenoord, Jeroen Kolkman, Koen Bellens, Kim Van Beek, et al.

    Objective We evaluated the histamine 1 receptor antagonist ebastine as a potential treatment for patients with non-constipated irritable bowel syndrome (IBS) in a randomised, placebo-controlled phase 2 study. Methods Non-constipated patients with IBS fulfilling the Rome III criteria were randomly assigned to 20 mg ebastine or placebo for 12 weeks. Subjects scored global relief of symptoms (GRS) and abdominal pain intensity (API). A subject was considered a weekly responder for GRS if total or obvious relief was reported and a responder for API if the weekly average pain score was reduced by at least 30% vs baseline. The primary endpoints were the proportion of subjects who were weekly responders for at least 6 out of the 12 treatment weeks for both GRS and API (‘GRS+API’, composite endpoint) and for GRS and API separately. Results 202 participants (32±11 years, 68% female) were randomly allocated to receive ebastine (n=101) or placebo (n=101). Treatment with ebastine resulted in significantly more responders (12%, 12/92) for GRS+API compared with placebo (4%, 4/87, p=0.047) while the proportion of responders for GRS and API separately was higher for ebastine compared with placebo, although not statistically significant (placebo vs ebastine, GRS: 7% (6/87) vs 15% (14/91), p=0.072; API: 25% (20/85) vs 37% (34/92), p=0.081). Conclusions Our study shows that ebastine is superior to placebo and should be further evaluated as novel treatment for patients with non-constipated IBS. Trial registration number The study protocol was approved by the local ethics committee of each study site (EudraCT number: 2013-001199-39; ClinicalTrials.gov identifier: NCT01908465).